---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277564"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:46:15.749286+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MAIA terminates ATM facility, faces NYSE delisting notice; CFO and CMO fired

## Summary
- Terminated at-the-market equity sales agreement with ThinkEquity; had raised ~$1.67M through Nov 15, 2023.
- NYSE American orally advised MAIA of non-compliance with stockholders' equity rule ($2.7M vs $4M minimum).
- CFO Joseph McGuire and CMO Dr. Mihail Obrocea terminated effective Nov 10; severance $330k and $418k respectively.
- Jeffrey Himmelreich appointed Head of Finance and principal accounting officer; base salary $210k.

## SEC filing metadata
- accession: 0001193125-23-277564
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 3.01, 8.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/d882839d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277564
- JSON: https://secwatch.observer/filing/0001193125-23-277564.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277564.txt

## Key facts
- Executive change
  Joseph McGuire was terminated as Chief Financial Officer at MAIA Biotechnology, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm
- Executive change
  Dr. Mihail Obrocea was terminated as Chief Medical Officer at MAIA Biotechnology, Inc..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm
- Executive change
  Jeffrey Himmelreich was appointed as Head of Finance at MAIA Biotechnology, Inc..
  - Action: appointed
  - Role: Head of Finance
  source text: On the same date, the Company appointed Jeffrey Himmelreich as its Head of Finance and principal financial and accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm
- Material Agreements
  MAIA Biotechnology, Inc. terminated Sales Agreement with ThinkEquity LLC valued at upsize total offering amount of up to $7,000,000; gross proceeds of $1,667,084.40 from sale of 758,3 (effective 2023-11-15).
  - Action: termination
  - Agreement: atm program
  - Counterparty: ThinkEquity LLC
  - Value: upsize total offering amount of up to $7,000,000; gross proceeds of $1,667,084.40 from sale of 758,3
  - Effective: 2023-11-15
  source text: On November 15, 2023, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain Sales Agreement, dated as of September 1, 2023 (the “Sales Agreement”), between the Company and ThinkEquity LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the Sales Agreement, which termination will be effective 10 days after November 15, 2023, in accordance with the terms of the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.